By JP Donahue | Peptides Costa Rica Editorial Team
Publish target: August 31, 2026

Educational content only. Nothing in this article constitutes medical advice or a recommendation to use an investigational or unapproved compound. Peptides Costa Rica products are intended strictly for laboratory research use only and not for human or veterinary use.

SLU-PP-332 is often discussed online as an “exercise mimetic,” but two facts should come first: it is not a peptide, and the published evidence remains preclinical.

SLU-PP-332 is a synthetic small molecule designed to activate estrogen-related receptors, or ERRs. These receptors help regulate genes involved in mitochondrial function, energy use, and some of the metabolic changes associated with exercise.

In cell and mouse studies, researchers have reported changes in mitochondrial respiration, oxidative muscle characteristics, endurance, fatty-acid metabolism, energy expenditure, and other metabolic measures.

Those findings make SLU-PP-332 an interesting laboratory research compound. They do not establish that it is safe or effective in humans, and they do not mean a compound can reproduce the complete biological effects of exercise.

First: SLU-PP-332 Is Not a Peptide

The name appears frequently in peptide catalogs, but chemically SLU-PP-332 is a small organic molecule, not an amino-acid chain.

That distinction matters. Peptides and small molecules can behave very differently in their structure, receptor interactions, solubility, metabolism, handling, and pharmacokinetics.

SLU-PP-332 is more accurately described as a small-molecule pan-ERR agonist because it activates all three members of the estrogen-related receptor family: ERRα, ERRβ, and ERRγ.

That terminology should be used consistently when discussing the compound.

What Are Estrogen-Related Receptors?

Estrogen-related receptors are a family of nuclear receptors known as ERRα, ERRβ, and ERRγ.

Despite the similar name, ERRs are not the same as classical estrogen receptors.

ERRs play an important role in regulating cellular energy metabolism. Their activity is connected with mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation, the Krebs cycle, and metabolic adaptations in skeletal and cardiac muscle.

Because endurance exercise changes many of these same biological pathways, researchers became interested in whether activating ERRs pharmacologically could reproduce selected features of the exercise response.

That is the scientific context in which SLU-PP-332 was developed.

Why Is SLU-PP-332 Called an “Exercise Mimetic”?

The “exercise mimetic” label comes primarily from research showing that SLU-PP-332 can reproduce selected molecular and metabolic effects associated with aerobic exercise in experimental models.

In its original 2023 characterization, researchers reported that SLU-PP-332 activated all three ERR subtypes, with particularly strong activity at ERRα.

In skeletal-muscle cells, the compound increased mitochondrial function and cellular respiration.

In mice, researchers reported an increase in type IIa oxidative muscle fibers along with improved exercise endurance.

The compound also activated an ERRα-dependent gene-expression program that overlapped with biological responses observed during acute aerobic exercise.

That overlap is the basis for the “exercise mimetic” description.

It is important, however, not to stretch the term beyond what the research demonstrates.

Exercise affects the cardiovascular system, nervous system, musculoskeletal system, bone, metabolism, insulin sensitivity, immune function, mood, coordination, mechanical loading, and numerous other biological systems.

Activating several exercise-related molecular pathways is not the same thing as recreating exercise.

What Did the Metabolic-Syndrome Research Show?

A 2024 study examined SLU-PP-332 in mouse models of obesity and metabolic syndrome.

Researchers reported increased energy expenditure and fatty-acid oxidation, reduced fat-mass accumulation, and improved insulin sensitivity in the models studied.

Those findings attracted considerable attention because they suggested that pharmacological activation of ERR pathways could influence whole-body energy metabolism.

But the experimental context matters.

These were controlled experiments in mice, including diet-induced and genetically obese models. They were not human weight-loss studies.

Animal models allow scientists to test biological mechanisms under controlled conditions. They do not establish what the same compound will do in people.

The strongest conclusion supported by this research is that SLU-PP-332 altered important metabolic pathways and whole-body metabolic measures in the mouse models studied.

That is scientifically significant.

It is still preclinical evidence.

What Does the Research Say About Mitochondria?

Mitochondrial biology is central to the SLU-PP-332 research because ERRs regulate numerous genes associated with oxidative metabolism.

The original skeletal-muscle research reported increased mitochondrial respiration in cultured muscle cells.

Later research expanded ERR agonism into other tissues and disease models.

In a pressure-overload heart-failure model in mice, SLU-PP-332 and the related agonist SLU-PP-915 activated metabolic genes associated with fatty-acid metabolism and mitochondrial function.

Researchers reported improvements in several cardiac measures in that experimental model and identified ERRγ as an important contributor to the observed cardiometabolic response.

Another study examined SLU-PP-332 in aged mice in connection with mitochondrial dysfunction and inflammatory signaling in the kidney.

Together, these studies strengthen the case for ERR signaling as an important research target in mitochondrial and metabolic biology.

They do not establish SLU-PP-332 as an approved treatment for cardiac, kidney, metabolic, or age-related disease.

The Oral-Bioavailability Problem Is Important

One of the most important developments in the newer SLU research is greater attention to the limitations of the original molecule itself.

A 2026 paper examining the related compound SLU-PP-915 states that SLU-PP-332 lacks oral bioavailability.

SLU-PP-915 was developed as a chemically distinct pan-ERR agonist with improved pharmacokinetic properties and oral activity in mice.

This distinction is important because the biological target and the molecule used to investigate that target are not the same thing.

A compound can produce scientifically interesting results while still having chemical or pharmacokinetic limitations that make it a poor candidate for conventional drug development.

A separate 2026 structure-activity relationship study examined modifications to the SLU-PP-332 chemical structure.

SLU-PP-332 remained an important benchmark, but researchers identified related analogues with improvements in properties including solubility, ligand efficiency, and metabolic stability.

In other words, the research program did not stop with the original molecule.

SLU-PP-332 helped establish the biological concept. Researchers then began using that knowledge to investigate potentially improved compounds.

What Do the 2026 Metabolism Studies Add?

Researchers have also started examining how SLU-PP-332 is metabolized in laboratory systems.

A 2026 study from the UCLA Olympic Analytical Laboratory used pooled human-liver S9 fractions to identify in-vitro Phase I and Phase II metabolites of SLU-PP-332.

Investigators identified multiple hydroxylated, reduced, glucuronidated, and sulfated metabolites.

Part of the purpose of this work was analytical. Exercise mimetics and metabolic modulators are relevant to doping-control research, making the identification of metabolites useful for laboratory detection.

This research adds important information about how SLU-PP-332 may be chemically transformed.

It should not be confused with a human pharmacokinetic trial.

The researchers used human-derived liver material in a laboratory system. They were not administering SLU-PP-332 to human research participants.

That distinction is particularly important when interpreting headlines or summaries that use the word “human” simply because human-derived biological material was used in an experiment.

Does SLU-PP-332 Have Human Clinical Evidence?

The published evidence reviewed for this guide remains dominated by biochemical, cell, tissue, and animal research.

The major findings involving exercise endurance, metabolism, mitochondrial function, cardiac models, kidney models, metabolism, and oral bioavailability remain preclinical.

That means the existing evidence does not justify converting mouse findings into claims about human fat loss, endurance, insulin sensitivity, cardiovascular function, longevity, or athletic performance.

There is also no established clinical dosing framework, clinical safety profile, or proven therapeutic benefit that can be inferred from the research discussed here.

For a research supplier, the appropriate description remains straightforward:

SLU-PP-332 is an investigational small-molecule research compound used to study ERR signaling and related metabolic pathways.

Why SLU-PP-332 Is Still Scientifically Interesting

The limitations of SLU-PP-332 do not make the research unimportant.

They help clarify why the molecule matters.

SLU-PP-332 helped demonstrate that ERRα, once considered difficult to target pharmacologically, could be activated with a synthetic small molecule in vivo.

Researchers could then investigate how ERR activation affected exercise-responsive transcription, oxidative muscle phenotype, mitochondrial metabolism, and whole-body energy use.

SLU-PP-332 also provided medicinal chemists with a chemical scaffold that could be modified and improved.

The 2026 structure-activity research illustrates how early experimental compounds often contribute to drug discovery.

Their importance is not necessarily that they become finished drugs themselves. Their value may be in revealing which chemical features control receptor activity, which biological pathways are worth pursuing, and which properties of the original molecule need improvement.

That is a much more accurate way to understand SLU-PP-332 than calling it “exercise in a bottle.”

How Researchers Should Evaluate SLU-PP-332 Material

When evaluating SLU-PP-332 for laboratory research, several questions matter:

1. Is the compound identity clearly documented?
2. Does the batch have analytical evidence supporting identity and purity?
3. Does the research being cited examine SLU-PP-332 specifically rather than a related ERR agonist?
4. Are conclusions limited to the cell, tissue, or animal model actually studied?
5. Are limitations such as oral bioavailability acknowledged?
6. Does the experimental design adequately distinguish ERR-specific effects from broader metabolic changes?

Peptides Costa Rica provides product information and batch documentation for research materials. Researchers should match that documentation to the requirements of their own validated laboratory protocols.

The Bottom Line

SLU-PP-332 is a small-molecule pan-ERR agonist, not a peptide.

It earned the “exercise mimetic” label because preclinical studies showed that ERR activation could reproduce selected aerobic-exercise-related gene-expression and metabolic changes in cells and mice.

Mouse studies have reported changes in endurance, oxidative muscle characteristics, fatty-acid metabolism, energy expenditure, metabolic-syndrome measures, and mitochondrial function.

Newer research has also clarified limitations of the original molecule, including its lack of oral bioavailability, while identifying opportunities to improve properties such as solubility and metabolic stability through related compounds.

The strongest conclusion is not that SLU-PP-332 replaces exercise or has proven human benefits.

It is that SLU-PP-332 has become a useful experimental tool for understanding ERR biology, mitochondrial metabolism, exercise-responsive pathways, and the development of next-generation ERR agonists.

Educational content only. Nothing in this article constitutes medical advice or a recommendation to use an investigational or unapproved compound. Peptides Costa Rica products are intended strictly for laboratory research use only and not for human or veterinary use.

Frequently Asked Questions

Is SLU-PP-332 a peptide?

No. SLU-PP-332 is a synthetic small molecule. It does not have an amino-acid sequence and should not be chemically described as a peptide.

Why is SLU-PP-332 called an exercise mimetic?

Preclinical research found that ERR activation with SLU-PP-332 produced selected gene-expression and metabolic changes associated with aerobic exercise and improved endurance in mice. The term refers to those experimental similarities, not to complete replacement of exercise.

What receptors does SLU-PP-332 target?

SLU-PP-332 is described as a pan-agonist of ERRα, ERRβ, and ERRγ. The original characterization reported particularly strong activity at ERRα.

Does SLU-PP-332 increase mitochondria?

Published cell and animal studies report changes in mitochondrial respiration, oxidative metabolism, mitochondrial-associated gene programs, and related measures. Those findings remain preclinical.

Has SLU-PP-332 been proven for weight loss in humans?

No. The metabolic and body-fat findings reported in the published research come from mouse models, not human weight-loss trials.

Is SLU-PP-332 orally bioavailable?

A 2026 paper from the research program states that SLU-PP-332 lacks oral bioavailability. The related compound SLU-PP-915 was developed with improved oral pharmacokinetic properties in mice.

Is SLU-PP-332 the same as SLU-PP-915?

No. They are chemically distinct pan-ERR agonists. SLU-PP-915 is a later research compound with different pharmacokinetic properties and should not be treated as interchangeable with SLU-PP-332.

Is SLU-PP-332 approved for human use?

The research discussed here remains preclinical. Peptides Costa Rica supplies SLU-PP-332 strictly as a laboratory research compound and not for human or veterinary use.

Glossary of Terms Used in This Article

Agonist: A molecule that binds to a receptor and activates it, producing a biological response.

Analytical chemistry: The branch of chemistry concerned with identifying substances and determining how much of them is present.

Analogue: A chemically related version of a compound that has been modified to alter properties such as potency, solubility, or stability.

Bioavailability: The proportion of a compound that reaches circulation in an active form after administration by a particular route.

Cellular respiration: The processes cells use to convert nutrients into usable energy.

ERR / estrogen-related receptor: A family of nuclear receptors consisting of ERRα, ERRβ, and ERRγ that help regulate genes involved in energy metabolism and mitochondrial function.

Exercise mimetic: An experimental compound intended to reproduce selected molecular or metabolic effects associated with exercise. It does not reproduce exercise as a whole.

Fatty-acid oxidation: The process by which cells break down fatty acids to generate energy.

Gene expression: The process through which information encoded in DNA is used to influence cellular activity, including the production of RNA and proteins.

Glucuronidation: A Phase II metabolic process in which glucuronic acid is attached to a compound or metabolite.

Hydroxylation: A common metabolic reaction in which a hydroxyl group is added to a molecule.

In vitro: Research performed outside a living organism, such as in cultured cells, isolated enzymes, or prepared tissue fractions.

In vivo: Research performed within a living organism.

Insulin sensitivity: The responsiveness of cells and tissues to insulin signaling.

Krebs cycle: A central series of cellular reactions involved in extracting energy from nutrients. It is also called the citric-acid cycle or TCA cycle.

Ligand: A molecule that binds to a receptor or other biological target.

Ligand efficiency: A medicinal-chemistry measure comparing biological activity or binding with the molecular size of a compound.

Metabolic stability: How resistant a compound is to chemical transformation or breakdown by metabolic enzymes.

Metabolite: A chemical product formed when a compound is transformed by cells, enzymes, or tissues.

Metabolic syndrome: A cluster of metabolic abnormalities that commonly includes impaired glucose regulation, abnormal blood lipids, excess abdominal fat, and elevated blood pressure.

Mitochondria: Cellular structures responsible for much of the energy production required by cells.

Mitochondrial biogenesis: The cellular process through which mitochondrial mass, number, or functional capacity increases.

Mitochondrial respiration: Oxygen-dependent processes within mitochondria involved in cellular energy production.

Nuclear receptor: An intracellular receptor capable of regulating gene expression after activation.

Oral bioavailability: The amount of an administered compound that reaches circulation in active form after being taken orally.

Oxidative metabolism: Energy-producing metabolic pathways that rely heavily on oxygen-dependent processes.

Oxidative phosphorylation: The mitochondrial process in which oxygen-dependent electron transport is used to generate ATP.

Pan-agonist: An agonist capable of activating multiple members of the same receptor family.

Pharmacokinetics: The study of the absorption, distribution, metabolism, and elimination of a compound over time.

Phenotype: An observable characteristic produced through the interaction of genes, cellular activity, and environment.

Phase I metabolism: Metabolic reactions that chemically modify a molecule, commonly through processes such as oxidation, reduction, or hydroxylation.

Phase II metabolism: Metabolic reactions that attach chemical groups to a compound or Phase I metabolite, including glucuronidation and sulfation.

Preclinical: Research conducted before established human clinical testing, including biochemical, cell, tissue, and animal studies.

Receptor: A biological molecule that recognizes specific ligands and can initiate or alter cellular signaling.

S9 fraction: A laboratory preparation derived from homogenized liver tissue that contains multiple types of metabolic enzymes and is used to study compound metabolism.

Scaffold/chemical scaffold: The core molecular structure used as a starting framework for designing related compounds.

Small molecule: A relatively low-molecular-weight chemical compound. Unlike a peptide, it is not defined by a chain of amino acids.

Solubility: The ability of a substance to dissolve in a particular liquid or solvent.

Structure-activity relationship (SAR): The study of how changes to a molecule’s chemical structure affect its biological activity and other properties.

Sulfation: A Phase II metabolic reaction in which a sulfate group is attached to a compound or metabolite.

Synthetic: Produced through chemical synthesis rather than isolated directly from a natural biological source.

Transcription: The process of copying genetic information from DNA into RNA.

Type IIa muscle fiber: A relatively oxidative fast-twitch muscle fiber combining rapid contraction with greater aerobic capacity than more glycolytic fast-twitch fibers.

Suggested Primary and Authoritative References

1. Billon C, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology. 2023;18(4):756-771. PMID: 36988910.
2. Billon C, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics. 2024;388(2):232-240. PMID: 37739806.
3. Xu W, et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024;149(3):227-250. PMID: 37961903.
4. Wang et al. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. American Journal of Pathology. PMID: 37717940.
5. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. Journal of Pharmacology and Experimental Therapeutics. 2026. PMID: 41421047.
6. Avliyakulov NK, Sobolevsky T, Ahrens E. Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. Drug Testing and Analysis. 2026;18(3):439-450. PMID: 41688415.
7. Okda HE, et al. Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. International Journal of Biological Macromolecules. 2026;355:151450. PMID: 41850449.